Trial Profile
A randomized, double-blind, placebo controlled, cross-over, multi-center study to assess the effect of the GLP-1 analogue LY307161 in patients suffering from Irritable Bowel Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs LY 307161 (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Rose Pharma
- 05 Nov 2010 New trial record.